A commentary published in Gastroenterology updates the POWER framework, originally released in 2017, to reflect the GLP-1 revolution in obesity care.
The paper addresses key advances in obesity treatment, including GLP-1 receptor agonists, endoscopic bariatric therapies, expanded bariatric surgery indications, and precision medicine.
It incorporates the concept of clinical obesity, recognizing obesity as a chronic disease and moving beyond BMI alone.
Multidisciplinary models combining medications, endoscopic therapies, and surgery are emphasized.
Endoscopic sleeve gastroplasty and similar therapies are noted as effective options.
Genetics and precision medicine may improve treatment matching.
Combining GLP-1 drugs with endoscopic or surgical interventions may yield greater and more durable weight loss.
The commentary highlights gastroenterologists' and hepatologists' roles in managing obesity-related conditions like MASLD, GERD, and gallbladder disease.
Background
The commentary, "Revisiting POWER in the GLP-1 Age," was published in the American Gastroenterological Association's journal Gastroenterology on June 15, 2026. It updates the Practice Guide on Obesity and Weight Management, Education, and Resources (POWER) framework to reflect new treatment options and evidence.